MarketPulse

hyperphagia

4 articles
BenzingaBenzinga··Vandana Singh

Neurocrine Acquires Soleno for $2.9B to Dominate Rare Disease Market

Neurocrine acquires Soleno for $2.9B to gain Vykat XR, a rare disease blockbuster generating $190M in 2025 revenue.
SLNONBIXacquisitionFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Soleno's VYKAT XR Faces Legal Storm as Safety Concerns Tank Stock 40%

Soleno Therapeutics faces securities lawsuit after hyperphagia drug VYKAT XR launch falters amid safety concerns, driving shares down 40% since August short seller report.
SLNOstock declinesecurities class action
BenzingaBenzinga··The Law Offices Of Frank R. Cruz

SLNO Shareholders Sue Over Alleged Safety Disclosure Failures in PWS Drug Trial

Soleno Therapeutics faces securities fraud lawsuit alleging failure to disclose safety concerns about DCCR drug candidate between March 2025 and November 2026.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Soleno Therapeutics Hit With Class Action Over VYKAT Launch Failures and Safety Disclosures

$SLNO faces securities lawsuit alleging misleading safety claims for hyperphagia drug VYKAT XR. Stock crashed 40% after short seller report and management admissions of launch disruptions.
SLNOsecurities class actionclinical trial